Lubrizol Acquires Bavaria Medizin Technologie GmbH

15.07.2021 I Lubrizol Life Science – Health I Press release

The acquisition expands Lubrizol’s medical device design, development and manufacturing capabilities and adds expertise in drug-coated balloons and innovative catheter-based products

CLEVELAND, Ohio — The Lubrizol Corporation announces the acquisition of Bavaria Medizin Technologie GmbH (BMT), an innovative designer and manufacturer of both intravascular (coronary, peripheral, and cranial) and nonvascular devices, including drug-coated balloons, by its German subsidiary Lubrizol Deutschland GmbH from its current majority shareholder Custos Vermögensverwaltungs GmbH as well as from the minority shareholders.

This acquisition builds upon Lubrizol’s expertise in precision thermoplastic extrusion and product development, establishing Lubrizol as a true end-to-end partner to the global medical device and pharmaceutical industries.

With over 100 employees, BMT is headquartered near Munich, Germany and operates a manufacturing facility in Sibiu, Romania. A pioneer in catheter-based technologies, BMT developed the first commercial drug-coated balloon, the Paccocath™ catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. Additionally, BMT offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing (OEM) services, which include the manufacturing of subassemblies and components, sterilization, packaging and labeling, stent crimping, and logistics management.